Anna Azvolinsky

Learn More
Chromosome replication initiates at multiple replicons and terminates when forks converge. In E. coli, the Tus-TER complex mediates polar fork converging at the terminator region, and aberrant termination events challenge chromosome integrity and segregation. Since in eukaryotes, termination is less characterized, we used budding yeast to identify the(More)
Replication forks face multiple obstacles that slow their progression. By two-dimensional gel analysis, yeast forks pause at stable DNA protein complexes, and this pausing is greatly increased in the absence of the Rrm3 helicase. We used a genome-wide approach to identify 96 sites of very high DNA polymerase binding in wild-type cells. Most of these binding(More)
Populations of terrestrial or freshwater taxa that are separated by oceans can be explained by either oceanic dispersal or fragmentation of a previously contiguous land mass. Amphisbaenians, the worm lizards (approx. 165 species), are small squamate reptiles that are uniquely adapted to a burrowing lifestyle and inhabit Africa, South America, Caribbean(More)
The Saccharomyces cerevisiae DNA helicase Rrm3p is needed for normal fork progression through >1000 discrete sites scattered throughout the genome. Here we show that replication of all yeast chromosomes was markedly delayed in rrm3 cells. Delayed replication was seen even in a region that lacks any predicted Rrm3p-dependent sites. Based on the pattern of(More)
Assembly of hepatitis delta virus (HDV) in infected human hepatocytes involves association of the 1,679- nucleotide single-stranded genomic RNA (deltaRNA) with multiple copies of both small and large forms of the delta protein (deltaAg) to form a ribonucleoprotein particle which in turn interacts with envelope proteins of the natural helper virus, hepatitis(More)
NEW YORK — Therapeutic agents have traditionally fallen into two basic categories: small-molecule drugs that can be synthesized in the laboratory and larger ‘biologic’ drugs that must be extracted or produced from cell cultures or other living systems. But biology is not always so straightforward, and in recent years a third class of drugs has emerged that(More)
R esearchers are taking a patient's own T cells, arming the cells against that patient's cancer, and injecting them back into the patient. The approach is working on metastatic cancer patients who have otherwise run out of treatment options. To date, only a few leukemia patients have been treated with the chi-meric antigen receptor (CAR) technique, but(More)
The strength of chemotherapy drugs is their ability to kill tumor cells. Unfortunately, these treatments are nonspecific, destroying normal rapidly dividing cells, making these drugs toxic for cancer patients. Monoclonal antibodies, by contrast, can home in on a target found only on tumor cells. But binding well to a target on a tumor cell does not(More)
F our years ago, Alice Crisci was diagnosed with stage I breast cancer at age 31. She immediately brought up fertility preservation with her oncologist, who told her there was a 50% chance the chemotherapy treatment for breast cancer would leave her infertile. “I knew if they told me there was a 2% chance, I would have still wanted to pursue fertility(More)